Evaluation of hypoxia-inducible factor-1α (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: In vitro and xenograft studies

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 4, 2003, Pages 1184-1193

  Vordermark, Dirk ^a,b   Brown, J Martin ^a   Phil, D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Flow cytometry; Glioblastoma; Hypoxia inducible factor 1 ; Hypoxic markers; Tumor hypoxia

Indexed keywords

CELLS; CYTOLOGY; OXYGEN; PROTEINS; RADIOTHERAPY; TUMORS;

CYTOMETRY;

ONCOLOGY;

HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PIMONIDAZOLE; PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CELL SUSPENSION; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RADIOSENSITIVITY; REGULATORY MECHANISM; SIGNAL PROCESSING; TUMOR HYPOXIA; WESTERN BLOTTING; XENOGRAFT;

EID: 0038724686     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00289-X     Document Type: Article

References (35)

1. Aebersold D.M., Burri P., Beer K.T., et al. Expression of hypoxia-inducible factor-1alpha A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer . Cancer Res. 61:2001;2911-2916.
2. Birner P., Schindl M., Obermair A., et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60:2000;4693-4696.
3. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 85:2001;881-890.
4. Koukourakis M.I., Giatromanolaki A., Skarlatos J., et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 61:2001;1830-1832.
5. Birner P., Gatterbauer B., Oberhuber G., et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas Its impact on prognosis and on neoangiogenesis . Cancer. 92:2001;165-171.
6. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Hypoxia-inducible factor (HIF 1A and HIF 2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 53:2002;1192-1202.
7. Hui E.P., Chan A.T., Pezzella F., et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 8:2002;2595-2604.
8. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 13:2001;167-171.
9. Ryan H.E., Poloni M., McNulty W., et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60:2000;4010-4015.
10. Vukovic V., Haugland H.K., Nicklee T., et al. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res. 61:2001;7394-7398.
11. Vordermark D. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas Its impact on prognosis and on neoangiogenesis . Cancer. 94:2002;2317-2318. [letter].
12. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 41:1996;31-39.
13. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 38:1997;285-289.
14. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 48:1998;149-156.
15. Nordsmark M., Loncaster J., Chou S.C., et al. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys. 49:2001;581-586.
16. 2 tension. Am J Physiol. 271:1996;C1172-1180.
17. Hall E.J. Radiobiology for the radiologist. 3rd ed: 1988;J.B. Lippincott, Philadelphia.
18. Kovacs M.S., Hocking D.J., Evans J.W., et al. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer. 80:1999;1245-1251.
19. Olive P.L., Durand R.E., Raleigh J.A., et al. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer. 83:2000;1525-1531.
20. Semenza G.L. HIF-1 and tumor progression Pathophysiology and therapeutics . Trends Mol Med. 8:(4 Suppl.):2002;S62-S67.
21. Zagzag D., Zhong H., Scalzitti J.M., et al. Expression of hypoxia-inducible factor 1alpha in brain tumors Association with angiogenesis, invasion, and progression . Cancer. 88:2000;2606-2618.
22. Kvietikova I., Scheid A., et al. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 15:2001;1312-1314.
23. Vordermark D., Shibata T., Brown J.M. Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia. 3:2001;527-534.
24. Vordermark D., Menke D.R., Brown J.M. Similar radiation sensitivities of acutely and chronically hypoxic cells in HT 1080 fibrosarcoma xenografts. Radiat Res. 159:2003;94-101.
25. Stroka D.M., Burkhardt T., Desbaillets I., et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 15:2001;2445-2453.
26. Lee J., Siemann D.W., Koch C.J., et al. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer. 67:1996;372-378.
27. Webster L., Hodgkiss R.J., Wilson G.D. Cell cycle distribution of hypoxia and progression of hypoxic tumor cells in vivo. Br J Cancer. 77:1998;227-234.
28. Rofstad E.K., Maseide K. Radiobiological and immunohistochemical assessment of hypoxia in human melanoma xenografts Acute and chronic hypoxia in individual tumors . Int J Radiat Biol. 75:1999;1377-1393.
29. Wiesener M.S., Munchenhagen P.M., Berger I., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 61:2001;5215-5222.
30. Loncaster J.A., Harris A.L., Davidson S.E., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix . Cancer Res. 61:2001;6394-6399.
31. Airley R., Loncaster J., Davidson S., et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 7:2001;928-934.
32. Olive P.L., Aquino-Parsons C., MacPhail S.H., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 61:2001;8924-8929.
33. Brown J.M. SR 4233 (tirapazamine) A new anticancer drug exploiting hypoxia in solid tumours . Br J Cancer. 67:1993;1163-1170.
34. Shibata T., Giaccia A.J., Brown J.M. Hypoxia-inducible regulation of a prodrug activation enzyme for tumor-specific gene therapy. Neoplasia. 4:2002;40-48.
35. Miralbell R., Mornex F., Greiner R., et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme Report of European Organization for Research and Treatment of Cancer trial 22933 . J Clin Oncol. 17:1999;3143-3149.